Categories: Products (D)

Countries in WHO South-East Asia Region resolve to make essential medical products accessible, affordable to all

New Delhi, September 05, 2018: Member countries of WHO South-East Asia Region today committed to make essential medicines, vaccines, diagnostics and medical devices affordable and accessible to all, both within the Region and beyond.

“Access to safe, effective and affordable medical products vital to prevent sufferings and impoverishment resulting from high out-of-pocket expenses on healthcare  by families, especially the poor,” Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region, said, as health ministers and officials of the 11 Member countries signed the ‘Delhi Declaration’ to improve access to essential medical products.

Medical products are a major component of out-of-pocket health care spending which has pushed 65 million people into poverty in the WHO South-East Asia Region.

Though significant efforts have been made by countries in recent years, as improving access to essential medicines is a WHO flagship priority programme in the Region since 2014, challenges remain in providing the right medical products at the right time to those in need.

To overcome challenges, the Delhi Declaration calls for allocation of sufficient financial resources by countries, as part of overall health financing strategies, to reduce out-of-pocket payments of families on essential medicines.

The declaration calls for strengthening national policies, regulation, supply chain management, and capacity to leverage intellectual property and trade for public health, to improve access to medicines and vaccines.

Signing the declaration at the Seventy-first Regional Committee Session of WHO South-East Asia Region, Member countries committed to developing an effective, transparent and participatory mechanism for regional price negotiation and pooled procurement to ensure accessibility and affordability of essential medical products for life threatening and rare diseases.

The Member countries committed to strengthen regulatory cooperation and collaboration to improve availability, quality and safety of essential medical products through the South-East Asia Regulatory Network (SEARN).

With the Region emerging as a major manufacturer of essential medical products especially generic medicines, Member countries agreed to leverage this strength to improve accessibility and affordability both within the Region and beyond.

The Member countries committed to developing an essential medical products list, in particular essential diagnostics list, for improved patient care, affordability of quality tests, and greater capacity to diagnose diseases during outbreaks and strengthened capabilities of national laboratories.

The declaration also emphasized on more appropriate use of antibiotics; and innovation and investment in R&D including for neglected diseases, and affordable medical products.

The Member countries agreed to ensure universal accessibility and affordability of essential medical products by 2030, as part of achieving universal health coverage (UHC) and the health related goals of SDG 2030 agenda.

The Regional Committee is held annually and is hosted by one of the 11 Member countries or the WHO South-East Asia Regional Office.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

17 hours ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

3 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

4 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

5 days ago

SpOvum® Launches ARTGPT Redefining Patient Support in Assisted Reproductive Technology (ART)

Launched for 1st time in India, ARTGPT is designed to address queries regarding A.R.T treatments Product created…

1 week ago